Patients 12.06.2022
Science & Innovation 12.02.2022
Leveraging expertise in human genetics and biology, Amgen is developing multispecific medicines that target obesity, a complex biological disease with multiple underlying causes.
Patients 11.22.2022
Lee Paris cared for her mother in her final months under a lot of stress. Then her husband died of Covid. Now she looks ahead to the comfort of old traditions and new ones, too, with help from The Amgen Safety Net Foundation.
Leadership 11.16.2022
Amgen's VP of Global Development for Biosimilars has persevered in the face of challenges, and she was named one of the 2022 Fiercest Women in Life Sciences by Fierce Pharma.
Responsibility 11.10.2022
Science & Innovation 11.10.2022
Severe active ANCA-associated vasculitis therapy TAVNEOS® becomes the newest medicine in Amgen's inflammation portfolio after close of ChemoCentryx deal.
Five Takeaways from Amgen’s Roundtable on Climate Change and Human Health
PRESS RELEASE
Amgen is a pioneer in the science of using living cells to make biologic medicines.
Amgen’s medicines treat serious illnesses and typically address diseases with a limited number of treatment options.
Making a positive difference in the world is at the heart of what we do at Amgen—and it goes beyond making vital medicines.
Amgen is a pioneer in the science of using living cells to making biologic medicines, leading and guiding the biotech industry.
Encounter opportunities both new and undiscovered, as we embrace leading-edge technologies, invest in our talents, and maximize our potential.
